ZSZongxi Sun

Zongxi Sun

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Zongxi Sun has a total of 19 co-authors. Here are the top co-authors by number of shared publications:

  • Fengzhen Li

    Guangxi International Zhuang Medicine Hospital Affiliated to Guangxi University of Chinese Medicine, Nanning, China

    1 shared publication
  • Haili Huang

    Second Clinical Medical School, Guangxi University of Chinese Medicine

    1 shared publication
  • Hua Zhong

    International Zhuang Medicine Hospital Affiliated to Guangxi University of Chinese Medicine, No. 8 Qiuyue Road, Wuxiang New District, Nanning 530201, Guangxi, China

    1 shared publication
  • Huiqiong Guo

    Zhuang Medicine Clinical Medical College, Guangxi University of Chinese Medicine

    1 shared publication
  • Jie Liang

    School of Pharmacy, Guangxi University of Chinese Medicine, Nanning, Guangxi, China

    1 shared publication
  • Jing Liang

    Zhuang Medicine Clinical Medical College, Guangxi University of Chinese Medicine

    1 shared publication

Latest Publications

  • Open Access

    Sulfated polysaccharide-coated protein nanoparticles for enhanced delivery of psoralen in breast cancer therapy

    by Huiqiong Guo, Jing Liang, Haili Huang, Zimo Zhang, Xin Huang, Zongxi Sun, Yinghong Huang

    Introduction: Psoralen (PSO) is an anticancer agent with a potential role in breast cancer management. Its clinical application, however, is significantly limited by poor aqueous solubility and low bioavailability. Therefore, the development of advanced PSO delivery systems is essential to enhance its therapeutic potential. Methods: In this study, a novel nano-delivery platform was constructed by encapsulating PSO into zein nanoparticles (NPs) followed by surface modification with fucoidan (Fu), yielding PSO-Z/F NPs. Results: Successful surface modification was confirmed by a reversal in ζ potential from positive values to −24.8 ± 0.02 mV, an increase in particle size to 129.23 ± 0.18 nm, characteristic changes in sulfate-related Fourier transform infrared spectroscopy (FTIR) bands, and the appearance of an S 2p signal in X-ray photoelectron spectroscopy (XPS). The PSO-Z/F NPs exhibited a uniform spherical morphology, with an encapsulation efficiency of 73.13 ± 0.98% and a drug-loading capacity of 5.40 ± 0.35%. Cellular uptake of PSO-Z/F NPs was 1.6-fold higher than that of uncoated PSO-Z NPs ( P < 0.05). In vitro , PSO-Z/F NPs significantly suppressed the proliferation, migration, and invasion of 4T1 breast cancer cells. Specifically, wound closure rate decreased from 29.13 ± 3.33 % in the control group to 5.02 ± 2.86% ( P < 0.001). Compared with the PSO group, the number of migrated cells decreased from 220 ± 33 to 146 ± 20 ( P < 0.01), while that of invaded cells decreased from 144 ± 21 to 90 ± 8 ( P < 0.05). Moreover, PSO-Z/F NPs increased the total apoptosis rate from 6.45% in the control group to 17.98% ( P < 0.01). In addition, hemolysis assays showed reduced hemolytic activity, while serum-incubation studies confirmed improved colloidal stability, as evidenced by minimal changes in particle size and PDI over 7 days. Notably, in vivo and ex vivo fluorescence analysis of tumors and major organs in 4T1 tumor-bearing mice showed efficient tumor accumulation of PSO-Z/F NPs, and pharmacodynamic studies indicated enhanced tumor growth inhibition with an acceptable biosafety profile. Discussion: Overall, PSO-Z/F NPs may provide a potential nanoparticle-based delivery strategy for improving the therapeutic application of psoralen in breast cancer.

  • Open Access

    Isodon lophanthoides alleviates liver fibrosis via modulation of purine metabolism and NF-κB signaling pathway: insights from multi-omics analysis

    by Kuikui Chen, Jie Liang, Yong Tan, Yaohua Li, Xiaojiao Pan, Zhonghui Guo, Wentao Zhang, Zongxi Sun

    Background: Isodon lophanthoides, a core botanical drug in Yao ethnomedicine, has traditionally been used to treat jaundice-type hepatitis and cholecystitis. However, its therapeutic potential and mechanisms against liver fibrosis remain largely unexplored.Methods: The metabolites of I. lophanthoides water extract (ILW) were characterized by ultra-performance liquid chromatography (UPLC) and UPLC coupled with quadrupole time-of-flight mass spectrometry (Q-TOF/MS). A carbon tetrachloride (CCl4)-induced liver fibrosis mouse model was employed to evaluate the anti-fibrotic effects of ILW. An integrated multi-omics approach encompassing transcriptomics, proteomics, and metabolomics was used to elucidate the underlying mechanisms, further supported by Western blotting, targeted metabolite quantification, and enzyme-linked immunosorbent assay (ELISA).Results: Thirty-two metabolites were identified in ILW. Among them, the concentrations of caffeic acid, rosmarinic acid, schaftoside, and isoschaftoside were determined to be 1.10, 5.13, 0.12, and 0.18 mg·g-1, respectively. ILW treatment significantly reduced serum levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), procollagen type III (PC-III), collagen type IV (COL-IV), laminin (LN), and hyaluronic acid (HA) in liver fibrotic mice. Histopathological analyses showed that ILW significantly alleviated liver inflammation, collagen deposition, and fibrosis. Multi-omics analysis revealed that ILW’s anti-fibrotic effects are linked to modulation of purine metabolism and inhibition of the nuclear factor kappa-B (NF-κB) signaling pathway. High-dose ILW lowered hepatic levels of adenine, adenosine monophosphate (AMP), and inosine monophosphate (IMP), while increasing adenosine, hypoxanthine, and N6-methyladenosine (m6A). Furthermore, high-dose and medium-dose ILW downregulated key NF-κB-related proteins, including toll-like receptor 4 (TLR4), myeloid differentiation primary response 88 (MyD88), phosphorylated NF-κB, transforming growth factor beta 1 (TGF-β1), tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and interleukin-1 beta (IL-1β).Conclusion: ILW exerts protective effects against liver fibrosis by attenuating inflammation, fibrosis, and liver damage through modulation metabolism modulation and NF-κB pathway inhibition. These findings provide a scientific basis for the traditional use of I. lophanthoides in liver-related disorders.

  • Open Access

    Anti-inflammatory Properties of Tongfeng Li’an Granules in an Acute Gouty Arthritis Rat Model

    by Xiangpei Zhao, Zhaoyang Long, Hua Zhong, Rongping Lu, Juan Wei, Fengzhen Li, Zongxi Sun

    Objectives: To examine the anti-inflammatory properties and underlying mechanisms of Tongfeng Li'an Granules (TFLA), a traditional medicine, in acute gouty arthritis using a rat model. Materials and Methods: We identified 55 major compounds in TFLA via ultrahigh-performance liquid chromatography connected to quadrupole time-of-flight mass spectrometry (UPLC-TQF-MS/MS). Databases were employed for the prediction of potential targets, followed by PPI network construction as well as GO and KEGG analyses. After network-pharmacology-based analysis, a rat gouty arthritis model was used to validate the anti-inflammatory mechanism of TFLA. Results: UPLC-TQF-MS/MS and network pharmacology analyses revealed 55 active ingredients and 160 targets of TFLA associated with gouty arthritis, forming an ingredient-target-disease network. The PPI network identified 20 core targets, including TLR2, TLR4, IL6, NF kappa B, etc. Functional enrichment analyses highlighted the Toll-like receptor signaling pathway as significantly enriched by multiple targets, validated in in vivo experiments. Animal experiments demonstrated that TFLA improved pathological changes in gouty joint synovium, with decreased ankle joint circumference, serum IL6, IL10, and TNF alpha levels, as well as reduced protein and mRNA expression of NLRP3, TLR2, and TLR4 in ankle joint synovial tissue observed in the middle- and high-dose TFLA and positive control groups compared to the model group (p < 0.05). Conclusion: This research elucidated the pharmacological mechanisms of TFLA against gouty arthritis, implicating various ingredients, targets, and signaling pathways. Animal experiments confirmed TFLA's efficacy in alleviating inflammation in acute gouty arthritis by modulating Toll-like receptor signaling and NLRP3 expression.